Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Aerosol Combination Therapy of 13 Cis Retinoic Acid and Captopril for Treating Covid-19 Patients Via Indirect Inhibition of Transmembrane Protease, Serine 2 (TMPRSS2)

NCT04578236 is registered in ClinicalTrials.gov with Kafrelsheikh University as lead sponsor.

NCT NCT04578236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04578236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Aerosol Combination Therapy of 13 Cis Retinoic Acid and Captopril for Treating Covid-19 Patients Via Indirect Inhibition of Transmembrane Protease, Serine 2 (TMPRSS2)
Lead sponsor
Kafrelsheikh University
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2020
Completion date
January 31, 2021
Enrollment
360 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

covid19